If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[{"arm_group_label":"Non-ABC-containing cART regimen","arm_group_description":"The comparator group was treated with non-ABC-containing cART regimen. The current analysis will be based on a total of approximately 7,500 subjects who received non-ABC-containing regimen.","arm_type":""},{"arm_group_label":"ABC as part of cART regimen","arm_group_description":"The exposed group was treated with ABC as part of cART regimen. The current analysis will be based on a total of approximately 14,000 subjects who received ABC.","arm_type":""}],"assignment":"","brief_summary":"Some observational studies and randomized controlled trials (RCTs) suggest an association between abacavir (ABC) use and myocardial infarction (MI), while other observational studies and RCTs do not confirm this, including meta-analyses conducted on clinical trial data by GlaxoSmithKline (GSK), the United States (US) Food and Drug Administration (FDA) and independent researchers. Although the published evidence remains conflicting, and a plausible biological mechanism for this potential association has not yet been identified, ViiV Healthcare (VH) continues to monitor data as it becomes available. In addition to summary data from the previous meta-analysis in 2009, the current analysis will include data that were collected as part of GSK/VH-sponsored clinical trials from Phase II–IV of drug development since 2009.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Meta-analysis of Data from Clinical Trials","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:22:52","criteria":"- HIV-infected adult subjects with at least 24 weeks of cART exposure will be included in this analysis. - Subjects from the previous GSK 2009 meta-analysis of 52 GSK-sponsored clinical trials and from 14 GSK/VH-sponsored clinical trials will be included in analysis. - Only studies that were completed or for which the primary objective was completed, will be included.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Ongoing","display_status_internal":"RECSTATUS_O_ONGOING","endpoint":"","enrollment":"1","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"none","id":"e88f3333-921b-59e0-8857-706687618751","internal":{"content":null,"contentDigest":"9ce91a406b040790e0733db0a3f4ff2c","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"- HIV-infected adult subjects with at least 24 weeks of cART exposure will be included in this analysis. - Subjects from the previous GSK 2009 meta-analysis of 52 GSK-sponsored clinical trials and from 14 GSK/VH-sponsored clinical trials will be included in analysis. - Only studies that were completed or for which the primary objective was completed, will be included.","interventions":[{"arm_group_label":"Non-ABC-containing cART regimen","intervention_description":"The incidence of MIs and CADs will be calculated from frequencies of reported adverse events (AEs) in the included clinical trials. Incidence rate and relative rate of MI and CADs will be compared for exposed group of ABC as part of cART and comparator group of non-ABC-containing cART regimen.","intervention_name":"Incidence of MIs and CADs","intervention_type":"other"},{"arm_group_label":"ABC as part of cART regimen","intervention_description":"The incidence of MIs and CADs will be calculated from frequencies of reported adverse events (AEs) in the included clinical trials. Incidence rate and relative rate of MI and CADs will be compared for exposed group of ABC as part of cART and comparator group of non-ABC-containing cART regimen.","intervention_name":"Incidence of MIs and CADs","intervention_type":"other"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":["Abacavir","Safety","Meta-analysis","Myocardial Infarction","Human Immunodeficiency Virus (HIV)","Coronary Artery Disease"],"last_follow_up_date":"04/21/2017 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:46:27","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"None retained","number_of_groups":"0","observational_study_design":"Cohort","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Retrospective"},"official_title":"Abacavir Use and Risk for Myocardial Infarction and Coronary Artery Disease: Meta-analysis of Data from Clinical Trials","org_study_id":"207263","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["United States: No Health Authority"]},"phase":"phase 4","primary_compl_date":"04/21/2017 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"MI and coronary artery disease (CAD) events reported in subjects treated with ABC-containing Combination Antiretroviral Therapy (cART) regimens and in subjects treated with non-ABC-containing cART regimens","outcome_time_frame":"Up to 144 weeks post treatment initiation","outcome_safety_issue":"True"}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A","GSK"]},"start_date":"11/30/2016 00:00:00","study_type":"Observational","therapeutic_area":"","citations":[],"is_section_801":null}},"pageContext":{"studyId":"207263"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}